netFormulary NHS
Pan Mersey
Area Prescribing Committee
 Search
 Results

Looking for Adalimumab found 25 matches

Formulary items 4 matches
Sub Section Title / notes 2  matches
   
Formulary BNF Category
  Adalimumab Drugs affecting the immune response - 13.05.03
  Adalimumab Cytokine modulators - 10.01.03
  Adalimumab Cytokine inhibitors - 01.05.03
  Adalimumab Additional treatments used in the management of ophthalmic conditions not listed in BNF chapter 11 - 11.10
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE (2008) Adalimumab for the treatment of adults with psoriasis [TA146] (13.05.03)
link in drug section NICE (2010). Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [TA195] (10.01.03)
link in subsection NICE (2010). Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [TA195] (10.01.03)
link in subsection NICE (2010). Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis [TA199] (10.01.03)
link in subsection NICE (2015). Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis [TA373] (10.01.03)
link in drug section NICE (2016). Adalimumab for treating moderate to severe hidradenitis suppurativa [TA392] (13.05.03)
link in subsection NICE (2016). Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed [TA375] (10.01.03)
link in drug section NICE (2017). Adalimumab and dexamethasone for treating non-infectious uveitis [TA460] (11.04.01)
link in drug section NICE (2017). Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people [TA455] (13.05.03)
link in drug section NICE TA187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)  (01.05.03)
link in drug section NICE TA187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40) (01.05.03)
link in subsection NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (11.10)
link in drug section Pan Mersey (2018). ADALIMUMAB injection (Humira®) in rheumatological conditions (10.01.03)

SubSection Titles / notes  
Preparations for psoriasis - (13.05.02)
STATIC LIST | A B C - (29.01)

 

netFormulary